Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expressionGalectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potentialAntitumor activity of the proteinase inhibitor tetra-p-amidinophenoxyneopentane in a nude mouse model of human melanomaDetection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis.Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage.Schwannoma-like pleomorphic adenoma: a case report with review of the literature.Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cellsGalectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.A primary cutaneous adenoid-cystic carcinoma in a young woman. Differential diagnosis and clinical implications.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products.HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicityInvestigation of VOCs associated with different characteristics of breast cancer cellsInteraction between CD44 and hyaluronate is directly implicated in the regulation of tumor development.Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infectionLarge needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.A case of subacute cutaneous lupus erythematosus in a patient with mixed connective tissue disease: successful treatment with plasmapheresis and rituximab.Antiproliferative Effects of 1α-OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications.Diffuse Follicular Variant of Papillary Thyroid Carcinoma: A Case Report with a Revision of Literature.Oncocytic Variant of Medullary Thyroid Carcinoma: A Rare Case of Sporadic Multifocal and Bilateral RET Wild-Type Neoplasm with Revision of the LiteratureGalectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Warthin Tumor of the Parotid Gland: A Case Report and Literature Review.Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3.Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology.MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis.Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.Cytogenetic, molecular and phenotypic characterization of the newly established renal carcinoma cell line KJ29. Evidence of translocations for chromosomes 1 and 3.SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation.A very unusual thyroid tumor: a nodule with mature fat papillary hyperplasia and focal atypia.Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives.Case report: skin injury after contact with a red spine starfish, Protoreaster lincki.Galectin-3 is essential for proper bone cell differentiation and activity, bone remodeling and biomechanical competence in mice.Murine monoclonal antibody elicited with antibiotic-exposed Escherichia coli exerts protective capacity in experimental bacterial infections.Loss of miR-204 expression is a key event in melanoma.Mice with reduced expression of the telomere-associated protein Ft1 develop p53-sensitive progeroid traits.
P50
Q28190079-9ECD7328-7B0C-475D-99E9-440D4FE1329CQ28291923-14147C73-8399-46E1-86C2-8C40974CB098Q28341771-47B5A6C8-49B4-42AA-AB1C-F6F9327B34C4Q31104623-06E8E582-6661-482A-9B82-1AE6A1FA7795Q33385643-06627967-8B54-4CB8-A758-F2EA31F8E6A9Q33445268-AE96393F-24BF-428B-805D-FB348D29B013Q33619709-C074817D-6D44-419B-A64E-E87C9995911DQ34477775-6BEF0BA2-3563-4199-913E-6D5729880FAFQ34592232-79A96AF0-4374-4F13-BF38-F4077A083743Q34760197-FEBCF404-4C5D-44EE-B44C-7D438C895020Q35024484-C00C906B-1657-427E-AFAC-50C7A6D3FF80Q35754653-E81C86FD-789B-446F-88BF-EA10653BAFAFQ35832992-9F8778C0-8DD2-4602-86E3-AAF9C99F6C65Q35992807-771F85EB-8BFD-410F-9AC2-49FB61A0977FQ36363467-968269E0-A180-4358-A4AF-14EBB79382F2Q36370222-D8564D79-E9AF-4C90-B3C8-7928BA0F601FQ36612077-8E6F7D1E-A610-4D6A-8C51-E634C27F96B6Q37101109-1DCA369F-1F38-48CF-BA4A-85B3F36FE398Q37578871-56A87E03-2D2B-4E9A-AD68-AF82FD4EE6E2Q37579713-3F957A63-A97A-4568-A6F2-1D1043555B42Q37579719-0E74DD38-18B2-41D8-B64A-5793628599B5Q37680170-308A71BB-7756-45FC-8787-CF1BD01D3162Q38546347-E22A418E-B37B-4B14-87C3-426CCD2A3D78Q38769072-5075F4AB-2108-4C68-AB03-F8276E4C9E4CQ39284246-9DF3FBD8-1BED-4683-B3EA-A5C7470DDDBAQ39617806-425FA332-5FFE-42E2-B684-5D6B2E1CC620Q39886632-080F7FE8-689F-4FB8-B93D-8E23D7233DA8Q40273238-A1AF9B00-94CD-4880-9A64-096317E0227EQ40851540-26426F2F-DDC1-4BAB-82A7-D8798455A3E8Q41299288-D10468F5-548D-4588-86DF-FEEACAD64CA9Q42813067-B2F2D7D5-83DC-4EEA-A53B-8D89994B205EQ42939107-11E9A60A-AB7E-43E0-9D3D-C7B56611AB03Q44732856-C30AFF27-02B5-4EC8-9AE8-A50E4CEF8110Q47260838-59A62F16-9D70-446D-BA0E-64772132BF5FQ47696912-F2D0E517-321E-43E5-818E-F553D1D26C4FQ48371436-2E1F2E92-CD88-413D-B9C5-64AB7EECAA0FQ50047014-8A414234-C1D1-4023-BCEE-F89F6D55051EQ50147169-4FED7864-EC2E-431B-914C-3237E76D32D3Q51734980-74ADC25E-723F-41A3-90BE-0DCEC6A3A3F1Q52595866-38F1F96C-98DD-48FE-9A47-C968546BC0D8
P50
description
Italiaans politicus
@nl
Italian pathologist and politician
@en
anatomopatologo e politico italiano
@it
italienischer Politiker und Pathologe
@de
name
Armando Bartolazzi
@ast
Armando Bartolazzi
@ca
Armando Bartolazzi
@en
Armando Bartolazzi
@es
Armando Bartolazzi
@fr
Armando Bartolazzi
@ga
Armando Bartolazzi
@it
Armando Bartolazzi
@nl
Armando Bartolazzi
@pt
Armando Bartolazzi
@pt-br
type
label
Armando Bartolazzi
@ast
Armando Bartolazzi
@ca
Armando Bartolazzi
@en
Armando Bartolazzi
@es
Armando Bartolazzi
@fr
Armando Bartolazzi
@ga
Armando Bartolazzi
@it
Armando Bartolazzi
@nl
Armando Bartolazzi
@pt
Armando Bartolazzi
@pt-br
prefLabel
Armando Bartolazzi
@ast
Armando Bartolazzi
@ca
Armando Bartolazzi
@en
Armando Bartolazzi
@es
Armando Bartolazzi
@fr
Armando Bartolazzi
@ga
Armando Bartolazzi
@it
Armando Bartolazzi
@nl
Armando Bartolazzi
@pt
Armando Bartolazzi
@pt-br
P1053
K-9708-2016
P1153
56047238500
P1229
P19
P21
P27
P31
P3829
P4521
P496
0000-0001-7820-5127
P569
1961-02-11T00:00:00Z